Literature DB >> 2447199

Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo.

K S Kim1, J H Kang, A S Cross, B Kaufman, W Zollinger, J Sadoff.   

Abstract

Mouse hybridoma antibodies (IgG and IgM) to O side chain determinants of Escherichia coli strain Bort (O18ac:K1:H7) were evaluated for their in vitro and in vivo activities against E. coli strains. Both IgG and IgM were opsonic in vitro and protected newborn rats challenged with a K1 E. coli strain, but their activities were strain specific. The antibodies protected against a K1 strain possessing a homologous O serotype but not against one possessing a heterologous O serotype. These antibodies were not effective against the K5-encapsulated O18 E. coli strain (possessing a homologous O type) but protected against its unencapsulated derivative. The opsonic and protective activities of these antibodies were significantly greater with IgG than IgM. Both IgG and IgM, however, required complement for their activities. When IgM to lipopolysaccharide was given to newborn rats in conjunction with IgM monoclonal antibody to the group B meningococcal polysaccharide, the protective effect was significantly greater than that of either antibody alone. Combinations of two (or more) antibodies to different cell wall components may be more beneficial in preventing and treating E. coli infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2447199     DOI: 10.1093/infdis/157.1.47

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum.

Authors:  J Hellman; P M Loiselle; M M Tehan; J E Allaire; L A Boyle; J T Kurnick; D M Andrews; K Sik Kim; H S Warren
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  Escherichia coli K1 RS218 interacts with human brain microvascular endothelial cells via type 1 fimbria bacteria in the fimbriated state.

Authors:  Ching-Hao Teng; Mian Cai; Sooan Shin; Yi Xie; Kee-Jun Kim; Naveed Ahmed Khan; Francescopaolo Di Cello; Kwang Sik Kim
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

3.  Passive immunization to outer membrane proteins MLP and PAL does not protect mice from sepsis.

Authors:  Catherine H Valentine; Judith Hellman; Laura K Beasley-Topliffe; Aranya Bagchi; H Shaw Warren
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

4.  NlpI facilitates deposition of C4bp on Escherichia coli by blocking classical complement-mediated killing, which results in high-level bacteremia.

Authors:  Yu-ting Tseng; Shainn-Wei Wang; Kwang Sik Kim; Ying-Hsiang Wang; Yufeng Yao; Chien-Cheng Chen; Chi-Wu Chiang; Pao-Chuan Hsieh; Ching-Hao Teng
Journal:  Infect Immun       Date:  2012-07-16       Impact factor: 3.441

5.  Escherichia coli invasion of brain microvascular endothelial cells in vitro and in vivo: molecular cloning and characterization of invasion gene ibe10.

Authors:  S H Huang; C Wass; Q Fu; N V Prasadarao; M Stins; K S Kim
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

6.  Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Pollack; N L Koles; M J Preston; B J Brown; G B Pier
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

7.  Enhanced protection by use of a combination of anticapsule and antilipopolysaccharide monoclonal antibodies against lethal Escherichia coli O18K5 infection of mice.

Authors:  H Frasa; B Benaissa-Trouw; L Tavares; K van Kessel; M Poppelier; K Kraaijeveld; J Verhoef
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

8.  The K1 capsule is the critical determinant in the development of Escherichia coli meningitis in the rat.

Authors:  K S Kim; H Itabashi; P Gemski; J Sadoff; R L Warren; A S Cross
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

Review 9.  Current status of meningococcal group B vaccine candidates: capsular or noncapsular?

Authors:  J Diaz Romero; I M Outschoorn
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

Review 10.  Human Meningitis-Associated Escherichia coli.

Authors:  Kwang Sik Kim
Journal:  EcoSal Plus       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.